Current approaches to the targeted delivery of therapeutics such as gene-silencing nucleic acids have to date tended to focus on a single target cell receptor, but truly personalized treatments for many diseases, such as cancer, will require the ability to target potentially multiple cell types and their receptors, which will vary between individuals. This has been technologically challenging, not least from a design and production perspective. Researchers at Tel Aviv University (TAU) have now developed a flexible, self-assembling siRNA carrier platform that they claim can easily be customized to target any cell receptor. The technology, which doesn't rely on chemical conjugation, is based on membrane-anchored lipoprotein, or linker (anchored secondary scFv enabling targeting; ASSET), which is incorporated into siRNA-loaded lipid-based nanoparticles (LNPs), and which binds to the Fc region of antibodies. “The siRNA delivery targeted carriers constructed today hone in on specific cells and require chemical conjugation ...
Original Article: Self-Assembling Nanoparticles Claimed to Represent Personalized Medicine "Milestone"
NEXT ARTICLE